Objective To explore the research profile, topical changes, and trends in remimazolam anesthesia through bibliometrics‑based analysis. Methods Retrieved the core database of Web of Science about remimazolam from January 2010 to June 2023, and analyzed the distribution of year of publication, methodology, population, country/region, authors and institutions, distribution of publication sources, research hotspots, and co‑cited journals and literature in anesthesia research through bibliometrics methods and the information analysis software VOS viewer for co‑occurrence and clustering, and mapping. Results There were 360 articles related to remazolam, and the number of articles published in anesthesia‑related research increased year by year. Clinical research is the main focus, and the number of elderly patients exceeds that of pediatric patients in the study population. China is currently the country with the largest number of articles, while the United States is at the forefront of the citation frequency. There are 17 authors and 22 institutions with ≥5 publications on remazolam‑related studies. There are 8 journals with 10 or more articles. According to the analysis of research hotspots, "midazolam", "propofol", "safety", "sedation" and "anesthesia" were the terms of research hotspot. Furthermore, there were 35 articles with 20 or more total citations, with three of the top 10 co‑citations from the journal Anesthesia and Analgesia. Conclusions The role of remazolam in anesthesia has drawn increasing attention year by year. The current research hotspots include the sedative efficacy of remazolam in gastro enteroscopy, surgery, general anesthesia, and intensive care units. Remazolam is expected to become a widely used sedative drug in clinical practice.